RT Journal Article
SR Electronic
T1 The Rapid Deployment of a 3D Printed “Latticed” Nasopharyngeal Swab for COVID-19 Testing Made Using Digital Light Synthesis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.25.20112201
DO 10.1101/2020.05.25.20112201
A1 Bennett, Ian
A1 Bulterys, Philip L.
A1 Chang, Melody
A1 DeSimone, Joseph M.
A1 Fralick, Jennifer
A1 Herring, Marie
A1 Kabaria, Hardik
A1 Kong, Christina S.
A1 Larson, Blane
A1 Lu, Owen
A1 Maxner, Arielle
A1 Meyer, Elle
A1 Patterson, Shawn
A1 Pollack, Steven
A1 Rolland, Jason
A1 Schmidt, Steven
A1 Seshadri, Sridhar
A1 Swarup, Keshav
A1 Thomas, Chelsey
A1 Van Wert, Ryan
YR 2020
UL http://medrxiv.org/content/early/2020/05/27/2020.05.25.20112201.abstract
AB The novel coronavirus disease (COVID-19) has caused a pandemic that has disrupted supply chains globally. This black swan event is challenging industries from all sectors of the economy including those industries directly needed to produce items that safeguard us from the disease itself, especially personal protection equipment (N95 masks, face shields) and much needed consumables associated with testing and vaccine delivery (swabs, vials and viral transfer medium). Digital manufacturing, especially 3D printing, has been promulgated as an important approach for the rapid development of new products as well as a replacement manufacturing technique for many traditional manufacturing methods, including injection molding, when supply chains are disrupted. Herein we report the use of Digital Light Synthesis (DLS) for the design and large-scale deployment of nasopharyngeal (NP) swabs for testing of coronavirus SARS-CoV-2 infections in humans. NP swabs have been one of society’s essential products hardest hit by the supply chain disruptions caused by COVID-19. A latticed tip NP swab was designed and fabricated by DLS from a liquid resin previously developed and approved for use to make dental night guard devices. These latticed NP swabs demonstrated non-inferiority in a human clinical study of patients suspected of being infected with SARS-CoV-2.Competing Interest StatementAll authors affiliated with Carbon are compensated by and have an equity stake in Carbon, Inc. All authors affiliated with Resolution Medical are compensated by and have an equity stake in Resolution Medical, LLC.Clinical TrialThis study was reviewed and approved by the Stanford Institutional Review Board under protocol #55823. This was a non-interventional study with a Class 1 exempt medical device that did not assess participant health outcomes.Funding StatementNo external funding was used for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Stanford Institutional Review Board under protocol #55823. This was a non-interventional study with a Class 1 exempt medical device that did not assess participant health outcomes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the data is included directly in the manuscript.